Literature DB >> 25917100

C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis.

Lin Zhang1, Shan-Hui Liu1, Tyler T Wright2, Zhi-Yuan Shen1, Hai-Yun Li1, Wei Zhu3, Lawrence A Potempa4, Shang-Rong Ji5, Alexander J Szalai6, Yi Wu7.   

Abstract

Human C-reactive protein (CRP) is a serum-soluble pattern recognition receptor that serves as a marker of inflammation and directly contributes to innate immunity. In this study, we show that human CRP also directly contributes to adaptive immunity, that is, native CRP binds specifically to human Jurkat T cells and to mouse naive CD4(+) T cells and modulates their Th1 and Th2 responses. In vitro both exogenously added (purified) and endogenously expressed (via transfection) human CRP inhibited Th1 differentiation and augmented Th2 differentiation of naive CD4(+) T cells. In vivo for human CRP transgenic compared with wild-type mice, a lesser proportion of the T cells recovered from the spleens of healthy animals were Th1 cells. Moreover, in both CRP transgenic mice and in wild-type mice treated with human CRP, during myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis both the Th1 cell response and disease severity were inhibited. These pattern recognition-independent actions of CRP directly on T cells highlights the potential for this soluble pattern recognition receptor to act as a tonic regulator of immunity, shaping global adaptive immune responses during both homeostasis and disease.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917100      PMCID: PMC4433796          DOI: 10.4049/jimmunol.1402909

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

Review 2.  Innate and adaptive immune responses in asthma.

Authors:  Stephen T Holgate
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

3.  C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R.

Authors:  Carolyn Mold; Wilfredo Rodriguez; Bojana Rodic-Polic; Terry W Du Clos
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

4.  Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein.

Authors:  Alexander J Szalai; Serge Nataf; Xian-Zhen Hu; Scott R Barnum
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

Review 5.  TLR-dependent T cell activation in autoimmunity.

Authors:  Kingston H G Mills
Journal:  Nat Rev Immunol       Date:  2011-11-18       Impact factor: 53.106

6.  Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein.

Authors:  H Moriwaki; N Kume; T Sawamura; T Aoyama; H Hoshikawa; H Ochi; E Nishi; T Masaki; T Kita
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-10       Impact factor: 8.311

7.  Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells.

Authors:  Dapeng Li; Gabrielle Romain; Anne-Laure Flamar; Dorothée Duluc; Melissa Dullaers; Xiao-Hua Li; Sandra Zurawski; Nathalie Bosquet; Anna Karolina Palucka; Roger Le Grand; Anne O'Garra; Gerard Zurawski; Jacques Banchereau; Sangkon Oh
Journal:  J Exp Med       Date:  2012-01-02       Impact factor: 14.307

8.  C-reactive protein does not opsonize early apoptotic human neutrophils, but binds only membrane-permeable late apoptotic cells and has no effect on their phagocytosis by macrophages.

Authors:  Simon P Hart; Karen M Alexander; Shonna M MacCall; Ian Dransfield
Journal:  J Inflamm (Lond)       Date:  2005-05-31       Impact factor: 4.981

9.  Effects on C-reactive protein on the lymphoid system. I. Binding to thymus-dependent lymphocytes and alteration of their functions.

Authors:  R F Mortensen; A P Osmand; H Gewurz
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

10.  Mutations of C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal cancer: implication for a CRP-Wnt crosstalk.

Authors:  Hai-Xiang Su; Hai-Hong Zhou; Ming-Yu Wang; Jin Cheng; Shi-Chao Zhang; Feng Hui; Xue-Zhong Chen; Shan-Hui Liu; Qin-Jiang Liu; Zi-Jiang Zhu; Qing-Rong Hu; Yi Wu; Shang-Rong Ji
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

View more
  20 in total

1.  An Intrinsically Disordered Motif Mediates Diverse Actions of Monomeric C-reactive Protein.

Authors:  Hai-Yun Li; Jing Wang; Fan Meng; Zhe-Kun Jia; Yang Su; Qi-Feng Bai; Ling-Ling Lv; Fu-Rong Ma; Lawrence A Potempa; Yong-Bin Yan; Shang-Rong Ji; Yi Wu
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

2.  Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk.

Authors:  Fabian Corlier; George Hafzalla; Joshua Faskowitz; Lewis H Kuller; James T Becker; Oscar L Lopez; Paul M Thompson; Meredith N Braskie
Journal:  Neuroimage       Date:  2018-01-28       Impact factor: 6.556

Review 3.  Regulation of C-reactive protein conformation in inflammation.

Authors:  ZhenYu Yao; Yanmin Zhang; HaiBin Wu
Journal:  Inflamm Res       Date:  2019-07-16       Impact factor: 4.575

4.  Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.

Authors:  Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Takashi Kumada
Journal:  Hepatol Int       Date:  2022-06-24       Impact factor: 9.029

5.  Probing the phosphocholine-binding site of human C-reactive protein by site-directed mutagenesis.

Authors:  A Agrawal; Y Xu; D Ansardi; K J Macon; J E Volanakis
Journal:  J Biol Chem       Date:  1992-12-15       Impact factor: 5.157

6.  Arctigenin Suppress Th17 Cells and Ameliorates Experimental Autoimmune Encephalomyelitis Through AMPK and PPAR-γ/ROR-γt Signaling.

Authors:  Wen Li; Zhihui Zhang; Kai Zhang; Zhenyi Xue; Yan Li; Zimu Zhang; Lijuan Zhang; Chao Gu; Qi Zhang; Junwei Hao; Yurong Da; Zhi Yao; Ying Kong; Rongxin Zhang
Journal:  Mol Neurobiol       Date:  2015-10-06       Impact factor: 5.590

Review 7.  Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.

Authors:  Max M Wattenberg; Gregory L Beatty
Journal:  Semin Cancer Biol       Date:  2020-01-15       Impact factor: 15.707

Review 8.  Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity.

Authors:  Kirsten M Baecher; Mandy L Ford
Journal:  Cancer Immunol Immunother       Date:  2021-07-09       Impact factor: 6.968

9.  Modular Approaches to Understand the Immunobiology of Human Immunodeficiency Virus Latency.

Authors:  Gideon Wolf; Nevil J Singh
Journal:  Viral Immunol       Date:  2021-02-17       Impact factor: 2.175

10.  Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab.

Authors:  Hitomi Jo; Tatsuya Yoshida; Hidehito Horinouchi; Shigehiro Yagishita; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Noboru Yamamoto; Kazuhisa Takahashi; Noriko Motoi; Yuichiro Ohe
Journal:  Cancer Immunol Immunother       Date:  2021-06-27       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.